PetMedix, a U.K.-based veterinary medicine startup, grabbed $37 million in Series B financing from Tencent, Kyoritsu Holdings, Digitalis Ventures, Parkwalk Advisors and Cambridge Innovation Capital.

Homage, a Singapore-based on-demand caregiving and health platform, fetched a $30 million Series C round led by Sheares Healthcare Group. New investors DG Daiwa Ventures and Sagana Capital also participated in the round, along with previous backers including HealthXCapital, SeedPlus, Trihill Capital and Alternate Ventures. Khoo Ee Ping, chief corporate development officer of Sheares Healthcare, will join the board.

EnteroBiotix, a Scotland-based startup developing microbial therapeutics that enhance the gut microbiome and target multiple indications, raised $21.5 million in Series A funding. Led by Thairm Bio, the round included support from Kineticos, Scottish Enterprise and SIS Ventures.

A-Alpha Bio Inc., a Seattle-based startup accelerating drug development with synthetic biology and next-generation sequencing, closed a $20 million Series A round. Madrona Venture Group led the investment, with Matt McIlwain joining the board. Perceptive Advisors' Perceptive Xontogeny Venture Fund and Lux Capital also participated in the funding, with Xontogeny's Ben Askew also added to the board.

Windgap Medical Inc., a Watertown, Mass.-based drug delivery platform, collected over $17 million in Series B1 funding. Taiwania Capital led the round, which included additional support from Molex Ventures and others.

Petabyte Technology, a Bellevue, Wash.-based veterinary software developer, secured $15 million in Series B funding from investors including Norwest Venture Partners, Halle Capital Management and Relevance Ventures.

More Health News

As a Delta wave peaks in some states, others brace for what's next

Covid-19 testing is keeping some students in school and out of quarantine

United gives staff more time to get Covid-19 vaccines

New AmeriCorps program aims to train next generation of health leaders

Around the Web

Eli Lilly bets on an RNA base-editing outfit, leveraging the body's own enzymes to reverse mutations. (Endpoints News)

Pandemic lockdown tied to worse outcomes in metastatic colorectal cancer, French study says. (STAT News)

BioNTech reports promising data on mRNA cocktail in mouse models of colon cancer and melanoma. (Fierce Biotech)

(END) Dow Jones Newswires

09-09-21 0956ET